Racura Oncology (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Racura Oncology Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Racura Oncology (ASX: RAC)
Latest News
Healthcare Shares
2 ASX healthcare shares outperforming on big news
Share Gainers
Why A2 Milk, Actinogen Medical, Karoon Energy, and Race Oncology shares are rising
Healthcare Shares
Guess which ASX healthcare stock is surging 15% on a 'major milestone'
52-Week Highs
3 ASX healthcare shares smashing new 52-week highs today
Share Gainers
Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher
Healthcare Shares
ASX healthcare stock surges 11% on 'incredibly valuable' FDA news
Share Gainers
Why Arizona Lithium, Bapcor, Race Oncology, and Tower shares are pushing higher
Share Gainers
Why Credit Corp, GUD, Race Oncology, and Spartan Resources shares are rising
Healthcare Shares
2 ASX healthcare shares rocking higher on big news
Healthcare Shares
Guess which ASX All Ords share is surging 16% after announcing a new finance chief
Share Fallers
Why Brainchip, Chalice Mining, Perseus, and Race Oncology shares are falling
Share Gainers
Why Lake Resources, Pro Medicus, Race Oncology, and Universal Store shares are rising today
Frequently Asked Questions
-
No, Racura Oncology does not pay dividends at this time.
-
Sydney-headquartered Racura Oncology listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
